 |
|
|---|---|
| Systematic (IUPAC) name | |
| (–)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H-benzo[d]naptho-(2,1-b)azepine | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 112108-01-7 |
| ATC code | None |
| PubChem | CID 107930 |
| UNII | 0X748O646K  |
| Chemical data | |
| Formula | C19H20ClNO |
| Mol. mass | 313.821 g/mol |
 (what is this?) (verify) |
|
Ecopipam (SCH-39166) is a synthetic benzazepine derivative drug that acts as a selective dopamine D1/D5 receptor antagonist, with little affinity for either dopamine D2-like or 5-HT2 receptors.[1] It has sedative, antipsychotic and anorectic effects, and was researched for human use although never approved for medical prescription, mainly because of side effects such as depression and anxiety.[2][3]
Chemical synthesis [edit]
Ecopipam can be synthesized from a simple tetralin derivative:[4]
Clinical trials [edit]
Ecopipam is currently being used in a clinical trial conducted by the biotechnology company Psyadon for the treatment of Lesch-Nyhan Syndrome,[5] as well as for Tourette syndrome.[6]
References [edit]
- ^ Chipkin RE, Iorio LC, Coffin VL, McQuade RD, Berger JG, Barnett A (December 1988). "Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity". The Journal of Pharmacology and Experimental Therapeutics 247 (3): 1093–102. PMID 2905002.
- ^ Hou D, Schumacher D (November 2001). "The selection of a commercial route for the D1 antagonist Sch-39166". Current Opinion in Drug Discovery & Development 4 (6): 792–9. PMID 11899619.
- ^ Astrup A, Greenway FL, Ling W, Pedicone L, Lachowicz J, Strader CD, Kwan R (July 2007). "Randomized controlled trials of the D1/D5 antagonist ecopipam for weight loss in obese subjects". Obesity (Silver Spring, Md.) 15 (7): 1717–31. doi:10.1038/oby.2007.205. PMID 17636090.
- ^ Hou, D; Schumacher, D (2001). "The selection of a commercial route for the D1 antagonist Sch-39166.". Current opinion in drug discovery & development 4 (6): 792–9. PMID 11899619.
- ^ http://www.psyadonrx.com/ongoingclinicaltrials.html
- ^ http://clinicaltrials.gov/ct2/show/study/NCT01244633
|
||||||||||||||||||||||||
Here you can share your comments or contribute with more information, content, resources or links about this topic.